The healthcare sector has faced several disruptions this year, and it seems we are not through with them yet. On May 22nd, the House of Representatives passed a bill proposing significant cuts to Medicaid and the Supplemental Nutrition Assistance Program (SNAP). So far, many of the recent changes have drawn concern regarding their potential impact on issues like state finances, infrastructure budgets and job stability.
The Good News
Amid this backdrop, the announcement of a new executive order aimed at lowering drug prices might sound like a step in a more promising direction. Earlier this week, President Trump introduced the “Most Favored Nation” (MFN) policy, which aims to tie U.S. drug prices to the lowest rates available in comparable countries. Under the policy, the MFN price is determined by the lowest rate in a registered Organization for Economic Co-operation and Development (OECD) country. That country’s G.D.P. per capita must also reach at least 60 percent of the U.S.’s.
With the goal of drastically reducing U.S. drug prices, Trump expects that Americans will no longer pay more for prescriptions than consumers elsewhere. The order pressures federal agencies, especially the Department of Health and Human Services, to act quickly. Within 30 days, the department is expected to outline how it will reduce drug prices under the new framework. Considering the many factors involved, the timeline is equally ambiguous and ambitious.
The Bad News
However, this has not gone over as well as they hoped, and pharmaceutical manufacturers have voiced concerns. Many are concerned that the proposed changes introduce uncertainty to future investment in drug development. Innovation in the industry often depends on long-term planning and predictable returns. If companies see these conditions eroding, it may affect their openness to new research and production efforts.
Additionally, the government has little direct control over patients with private insurance. Truthfully, government-funded programs like Medicare and Medicaid would see the majority of the intended effects. Questions also still remain about the recent budget proposals that include major cuts to Medicaid. Across the board, it is difficult to ensure that the savings from lower drug prices are passed on to patients.
Simultaneously, the new policy touches on international dynamics. Trump has expressed concern regarding how pharmaceutical companies profit from the U.S. market. He also stated that failure to respond to the situation could draw further scrutiny. Over the next 30 days, federal health leadership has been asked to negotiate with major pharmaceutical companies to address the issues. But, the U.S. has not demonstrated a strong commitment to fostering international collaboration in the health and medical sectors. For example, the U.S. initiated its withdrawal from the World Health Organization and implemented major healthcare funding cuts. These actions may undermine both domestic and international motivation for medical innovation.
Waiting in the Wings
It’s difficult to argue that this is an ideal moment for the U.S. to re-engage in dialogue aimed at expanding global cooperation in health policy. The cost of prescription drugs is a real and ongoing challenge for many Americans. Any effort to address this issue deserves careful attention.
Still, it’s worth recognizing that successful reform requires both coordination and continuity, not just urgency. If this new policy leads to meaningful dialogue and concrete improvements, it could be a step forward. Much will depend on how it’s implemented and whether broader efforts to support healthcare access and innovation remain a priority. For now, this is a moment of watchfulness in hopes that the recent bill will mark the beginning of a more thoughtful approach to drug pricing in the U.S.
Acknowledgement: The ideas expressed in this article are those of the individual author.
